Volume | 4,037,246 |
|
|||||
News | - | ||||||
Day High | 1.00 | Low High |
|||||
Day Low | 0.8804 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.92 | 0.8804 | 1.00 | 0.93 | 0.89 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
7,381 | 4,037,246 | $ 0.9433947 | $ 3,808,716 | - | 0.75 - 67.01 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:55 | formt | 3,592 | $ 0.92 | USD |
Sunshine Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
23.88M | 25.68M | - | 24.09M | -4.51M | -0.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sunshine Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.9002 | 1.16 | 0.83 | 0.8943783 | 3,976,307 | 0.0198 | 2.20% |
1 Month | 2.34 | 2.45 | 0.75 | 1.02 | 7,545,263 | -1.42 | -60.68% |
3 Months | 6.05 | 14.25 | 0.75 | 7.73 | 26,135,259 | -5.13 | -84.79% |
6 Months | 27.00 | 31.86 | 0.75 | 7.81 | 13,295,483 | -26.08 | -96.59% |
1 Year | 57.50 | 67.01 | 0.75 | 8.33 | 6,626,420 | -56.58 | -98.40% |
3 Years | 275.00 | 987.00 | 0.75 | 166.70 | 4,585,480 | -274.08 | -99.67% |
5 Years | 275.00 | 987.00 | 0.75 | 166.70 | 4,585,480 | -274.08 | -99.67% |
Sunshine Biopharma Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |